Protease inhibitors from marine actinobacteria as a potential source for antimalarial compound

PLoS ONE

Volumn 9, Issue 3, 2014, Pages

  Karthik, L ^a   Kumar, Gaurav ^a   Keswani, Tarun ^b   Bhattacharyya, Arindam ^b   Sarath Chandar, S ^a   Bhaskara Rao, K V ^a  

^a VIT UNIVERSITY   (India)

^b UNIVERSITY OF CALCUTTA   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; LYMPHOTOXIN; PROTEINASE INHIBITOR; TUMOR NECROSIS FACTOR ALPHA; CHYMOTRYPSIN; RNA 16S; SEA WATER; TRYPSIN;

ACTINOBACTERIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIMALARIAL ACTIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIOPLANKTON; BACTERIUM ISOLATE; COMPUTER MODEL; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG EFFICACY; IC 50; IN VITRO STUDY; IN VIVO STUDY; MALE; MOLECULAR DOCKING; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PARASITE CLEARANCE; PLASMODIUM BERGHEI INFECTION; PROTEINASE INHIBITION; RNA SEQUENCE; STREPTOMYCES; SURVIVAL; ANIMAL; ANTAGONISTS AND INHIBITORS; AQUATIC SPECIES; BIOLOGICAL MODEL; CHEMICAL STRUCTURE; CHEMISTRY; CLUSTER ANALYSIS; DISEASE MODEL; DNA BASE COMPOSITION; DOSE RESPONSE; DRUG EFFECTS; DRUG SENSITIVITY; ENZYME ACTIVATION; GENETICS; IC50; ISOLATION AND PURIFICATION; LIVER; MALARIA, FALCIPARUM; METABOLISM; MICROBIOLOGY; PARASITOLOGY; PATHOLOGY; PLASMODIUM FALCIPARUM; PROTEIN CONFORMATION; SPLEEN;

ACTINOBACTERIA; ANIMALS; ANTIMALARIALS; AQUATIC ORGANISMS; BASE COMPOSITION; CHYMOTRYPSIN; CLUSTER ANALYSIS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME ACTIVATION; INHIBITORY CONCENTRATION 50; LIVER; MALARIA, FALCIPARUM; MALE; MICE; MODELS, BIOLOGICAL; MODELS, MOLECULAR; PARASITIC SENSITIVITY TESTS; PLASMODIUM FALCIPARUM; PROTEASE INHIBITORS; PROTEIN CONFORMATION; RNA, RIBOSOMAL, 16S; SEAWATER; SPLEEN; TRYPSIN;

EID: 84897558635     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0090972     Document Type: Article

References (53)

1. WMR, 2011. World Malaria Report 2011. In: WHO (Ed.) Geneva.
2. WMR, 2011. World Malaria Report. Geneva.
3. Oaks SC, Mitchell VS, Pearson GW, Carpenter CCJ, editors. Malaria: obstacles and opportunities. Washington: National Academy Press; 1991.
4. Olliaro P, Cattani J,Wirth D (1996) Malaria, the submerged disease. JAMA 275: 230-3. (Pubitemid 26029597)
5. McKerrow JH, Sun E, Rosenthal PJ, Bouvier J (1993) The proteases and pathogenicity of parasitic protozoa. Annu Rev Microbiol 47: 821-853. (Pubitemid 23302954)
6. Vekemans J, Ballou WR (2008) Plasmodium falciparum malaria vaccines in development, Expert Rev Vaccines 7(2): 223-240 (Pubitemid 351357957)
7. Holder AA, Lockyer MJ, Odink KG, Sandhu JS, Riveros-Moreno V, et al. (1985) Primary structure of the precursor to the three major surface antigens of Plasmodium falciparum merozoites. Nature 317: 270-273. (Pubitemid 16246507)
8. Kauth CW, Woehlbier U, Kern M, Mekonnen Z, Lutz R, et al. (2006) Interactions between merozoite surface proteins 1, 6, and 7 of the malaria parasite Plasmodium falciparum. J Biol Chem 281: 31517-31527. (Pubitemid 46041417)
9. Pachebat JA, Ling IT, Grainger M, Trucco C, Howell S, et al. (2001) The 22 kDa component of the protein complex on the surface of Plasmodium falciparum merozoites is derived from a larger precursor, merozoite surface protein 7. Mol Biochem Parasitol 117: 83-89. (Pubitemid 32823485)
10. Stafford WH, Gunder B, Harris A, Heidrich HG, Holder AA, et al. (1996) A 22 kDa protein associated with the Plasmodium falciparum merozoite surface protein-1 complex. Mol Biochem Parasitol 80: 159-169. (Pubitemid 26313379)
11. Li X, Chen H, Oo TH, Daly TM, Bergman LW, et al. (2004) A Co-ligand complex anchors Plasmodium falciparum merozoites to the erythrocyte invasion receptor band 3. J Biol Chem 279: 5765-5771. (Pubitemid 38220607)
12. Pachebat JA, Kadekoppala M, Grainger M, Dluzewski AR, Gunaratne RS, et al. (2007) Extensive proteolytic processing of the malaria parasite merozoite surface protein 7 during biosynthesis and parasite release from erythrocytes. Mol Biochem Parasitol 151: 59-69. (Pubitemid 44895466)
13. Harris PK, Yeoh S, Dluzewski AR, O'Donnell RA, Withers-Martinez C, et al. (2005) Molecular identification of a malaria merozoite surface sheddase. PLoS Pathog 1: 241-251.
14. Blackman MJ (2000) Proteases involved in erythrocyte invasion by the malaria parasite: function and potential as chemotherapeutic targets. Curr Drug Targets 1: 59-83.
15. Yeoh S, O'Donnell RA, Koussis K, Dluzewski AR, Ansell KH, et al. (2007) Subcellular discharge of a serine protease mediates release of invasive malaria parasites from host erythrocytes. Cell 131:1072-1083. (Pubitemid 350235024)
16. Aly AS, Matuschewski K (2005) A malarial cysteine protease is necessary for Plasmodium sporozoite egress from oocysts. J Exp Med 202: 225-230. (Pubitemid 41043818)
17. Bode W, Huber R (1992) Natural protein proteinase inhibitors and their interaction with proteinases. Eur J Biochem 204:433-451.
18. Demuth HU (1990) Recent developments in inhibiting cysteine and serine proteases. J Enzyme Inhib 3:249-278.
19. Umezawa H (1972) Enzyme Inhibitor of Microbial Origin. Tokyo, Japan: University of Tokyo Press.
20. Drag M, Salvesen GS (2010) Emerging principles in protease-based drug discovery. Nat Rev Drug Discov 9: 690-701.
21. Ritchie DW, Kemp GJL (2000) Protein Docking Using Spherical Polar Fourier Correlations. PROTEINS: Struct Funct Genet 39: 178-194. (Pubitemid 30176485)
22. Karthik L, Gaurav Kumar, Bhaskara Rao KV (2010) Diversity of Marine Actinomycetes from Nicobar Marine sediments and its Antifungal Activity. Int J of Pharmacy and Pharmaceutical Sciences 2(1):199-203.
23. Peter IT, Anatoli VK (1998) The current global malaria situation. Malaria parasite biology, pathogenesis, and protection. ASM press. W.D.C. PP. 11-22.
24. David AF, Philip JR, Simon LC, Reto B, Solomon N (2004) Antimalarial drug discovery: Efficacy models for compound screening. Nat Rev Drug Discov 3:509-520.
25. WHO. (1980) The biology of malaria parasites: Report of a WHO Scientific Group. WHO Technical Report Series, 1980; 2.
26. Karthik L, Gaurav K, Tarun K, Arindam B, Palakshi R, et al. (2013) Marine Actinobacterial mediated Gold nanoparticles synthesis and their antimalarial activity. Nanomedicine 9(7):951-60.
27. Ohno H, Saheki T, Awaya J, Nakagawa A, Omura S (1978) Isolation and characterization of elasnin, a new human granulocyte elastase inhibitor produced by a strain of Streptomyces. J Antibiot (Tokyo) 31(11): 1116-23. (Pubitemid 9086602)
28. Nakagawa A, Ohno H, Miyano K, Omura S (1980) Structure of elasnin, a novel elastase inhibitor containing an. alpha.-pyrone ring. J Org Chem 45(16): 3268-3274.
29. Maskey RP, Halmke E, Kayser O, Fiebig HH, Maier A, et al. (2004) Anti-cancer and antibacterial trioxacarcins with anti-malaria activity from a marine Streptomycete and their absolute stereochemistry. J Nat Prod 57 (12): 771-779. (Pubitemid 40143893)
30. Peraud O (2006) Isolation and Characterization of a Sponge-Associated Actinomycete that Produces Manzamines. University of Maryland, College Park.
31. Prudhomme J, McDaniel E, Ponts N, Bertani S, Fenical W, et al. (2008) Marine actinomycetes: a new source of compounds against the human malaria parasite. PLoS One 3: 2335.
32. Macherla VR, Mitchell SS, Manam RR, Reed KA, Chao TH, et al. (2005) Structure-activity relationship studies of salinosporamide A (NPI-0052), a novel marine derived proteasome inhibitor. J Med Chem 48 (11): 3684-3687. (Pubitemid 40776841)
33. Sajid M, McKerrow JH (2002) Cysteine proteases of parasitic organisms. Mol Biochem Parasitol 120(1):1-21. (Pubitemid 34159288)
34. Yin H, Cao L, Xie M, Chen Q, Qiu G, et al. (2008) Bacterial diversity based on 16S rRNA and gyr B genes at Yinshan mine, China. Syst Appl Microbiol 31(4): 302-311.
35. Karthik L, Gaurav Kumar, Bhaskara Rao KV (2013) Antioxidant activity of newly discovered lineage of Marine actinobacteria. Asian Pac J Trop Med 6(4): 325-332.
36. Angelova L, Danova S, Iliev I, Ivanova I, Serkedjieva J (2005) Characterization of production of an extracellular proteinase inhibitor from Streptomyces chromofuscus 34-1 with alkaline phosphatase activity and antiviral effect. Biotechnol Biotechnol Equip 19 (2): 126-131. (Pubitemid 41056509)
37. Suda H, Aoyagi T, Hamada M, Takeuchi T, Umezawa H (1972) Antipain, a new protease inhibitor isolated from actinomycetes. J Antibiot (Tokyo) 25 (4): 263-266.
38. Umezawa S, Tatsuta K, Fujimoto K, Tsuchiya T, Umezawa H (1972) Structure of antipain, a new Sakaguchi-positive product of Streptomyces. J Antibiot (Tokyo) 25 (4): 267-270.
39. Taguchi S, Kikuchi H, Suzuki M, Kojima S, Terabe M, et al. (1993) Streptomyces subtilisin inhibitor-like proteins are distributed widely in Streptomycetes. Appl Environ Microbiol 59 (12): 4338-4341. (Pubitemid 23361428)
40. Umezawa H (1982) Low-molecular-weight enzyme inhibitors of microbial origin. Annu Rev Microbiol 36:75-99.
41. Umezawa H, Aoyagi T, Morishima H, Matsuzaki M, Hamada M (1970) Pepstatin, a new pepsin inhibitor produced by Actinomycetes. J Antibiot (Tokyo) 23 (5): 259-62.
42. Dondorp AM, Nosten F, Yi P, Das D, Phyo AP, et al. (2009) Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med 361 (5): 455-467.
43. WHO (2010) World malaria report. WHO Press, Geneva, ISBN 978 92 4 156410 6:58-62.
44. Rosenthal PJ (2004) Cysteine proteases of malaria parasites. Int J Parasitol 34: 1489-1499.
45. Olson JE, Lee GK, Semenov A, Rosenthal PJ (1999) Antimalarial Effects in Mice of Orally Administered Peptidyl Cysteine Protease Inhibitors. Bioorg Med Chem 7 (4): 633-8. (Pubitemid 29150306)
46. Lee M, Fridman R, Mobashery S (2004) Extracellular proteases as targets for treatment of cancer metastases. Chem Soc Rev 33 (7): 401-409. (Pubitemid 39456998)
47. Gelhaus C, Vicik R, Schirmeister T, Leippe M (2005) Blocking effect of a biotinylated protease inhibitor on the egress of Plasmodium falciparum merozoites from infected red blood cells. Biol Chem 386 (5): 499-502. (Pubitemid 41447592)
48. Ersmark K, Samuelsson B, Hallberg A (2006) Plasmepsins as potential targets for new antimalarial therapy. Med Res Rev 26 (5): 626-666. (Pubitemid 44230415)
49. Yeoh S, O'Donnell RA, Koussis K, Dluzewski AR, Ansell KH, et al. (2007) Subcellular discharge of a serine protease mediates release of invasive malaria parasites from host erythrocytes. Cell 131 (6): 1072-1083. (Pubitemid 350235024)
50. Senior K (2005) Battle against malaria could involve anti-HIV drugs. Drug Discov Today 10 (18): 1210.
51. McCoubrie JE, Miller SK, Sargeant T, Good RT, Hodder AN, et al. (2007) Evidence for a common role for the serine-type Plasmodium falciparum serine repeat antigen proteases: implications for vaccine and drug design. Infect Immun 75 (12): 5565-5574. (Pubitemid 350207793)
52. Putrianti ED, Schmidt-Christensen A, Arnold I, Heussler VT, Matuschewski K, et al. (2010) The Plasmodium serine-type SERA proteases display distinct expression patterns and non-essential in vivo roles during life cycle progression of the malaria parasite. Cell Microbiol 12 (6): 725-739.
53. Withers-Martinez C, Suarez C, Fulle S, Kher S, Penzo M, et al. (2012). Plasmodium subtilisin-like protease 1 (SUB1): insights into the active-site structure, specificity and function of a pan-malaria drug target. Int J Parasitol 42(6):597-612.